LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal ...
LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received FDA approval to expand its ongoing clinical trial to immediately fixate cranial flaps using TETRANITE ®, the company’s bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results